Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baizhiqian Lungs-Calming Antitussive Granules (also known as Baizhike Pingchuan Granules) is a Traditional Chinese Medicine (TCM) formulation developed by Dishang Group Weihai Dishang Bioproducts for the treatment of acute tracheobronchitis. It is specifically indicated for patients presenting with the "wind invading lung" pattern according to TCM diagnostics. The granules are designed to relieve cough and calm the lungs. A Phase II clinical trial (CTR20150308) was conducted as a randomized, double-blind, placebo-controlled study to evaluate its efficacy and safety over a 7-day treatment period followed by a 7-day follow-up in adult patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baizhiqian Lungs-Calming Antitussive Granules.